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Abstract
Single protein nanocapsules (SPNs) means that each indi-
vidual protein molecules are coated with a very thin polymer 
layer. The polymer chains which are porous enough to allow 
enzymatic functions are bound covalently to the protein mol-
ecule. According to our previous results the polymer layer can 
essentially stabilize different types of enzymes, e.g. its stability 
became to 50-70 times longer than that of the native ones. The 
heat stability (at 80 °C SPNs has activity after 24 hours) and 
the pH-stability (from pH = 1.5 to pH = 12.0) of the covered 
enzyme can essentially be improved comparing to the native 
enzymes. Our results show, that SPNs have a good features as 
drug carriers: acrylamide-bisacrylamide copolymer layer can 
carries bovine serum albumin molecules across the blood brain 
barrier in rat brain. We synthesized single haemoglobin nano-
capsules with acrylamide-bisacrylamide copolymer on the sur-
face of the molecules (PAAHgB) and their size, homogeneity, 
aggregation status, zeta potential were investigated compared 
with other nanomaterials. 
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1 Introduction
Proteins usually catalyze biological reactions and have 
enzymatic function. Enzymes are bioreactors with high spe-
cificity and selectivity. But enzymes have a great sensitivity 
and a relatively brief life-time [1]. The relatively short lifetime 
of enzymes and their sensibility to change in the environment 
(pH, temperature, mechanical stress, etc.) tends to limit their 
biotechnological application. The increase of the lifetime and 
stability of enzymes are crucial to widen usage of enzymes. 
Improvement in enzyme stability can reduce the amount of 
enzyme required, can extend the lifetime of enzymes and can 
increase the reuse of enzymes [2-7]. Enzyme immobilization 
to the surface or onto the inner cavities of greater structures 
with adsorption or covalent linkage is an effective strategy to 
increase its lifetime [2,3]. Covalent linkage between the enzyme 
molecule and carrier material can reduce the unfolding mecha-
nism of ternary structure of enzyme molecule and increase the 
stability of enzyme [4]. During the last decade there is a grow-
ing interest in minimized-size enzyme carriers [8,9]. 
Single enzyme nanocapsules (SEN), or single protein nano-
capsules (SPN) mean that a single protein molecule is covered 
with a few nanometer thick polymer layer [10-15] (Figure 1: 
Structure). This spatial polymer layer is thin and porous and 
allows the diffusion of substrate molecules to the active centre 
of the enzyme. Single enzyme nanoparticles involve the advan-
tages of the multi-point covalent attachment [4] and closing 
of molecules onto inner cavities [16]. This technique needs 
a special polymerization step: in situ polymerization starting 
from the previously modified surface of the protein molecules 
(“Grafting from” method [9]) (Figure 1: Structure).
The quaternary protein structures (e.g. tetrameric haemo-
globin molecules), as a functional unit does not change during 
the preparation of the single protein nanocapsules, i.e. cover-
ing enzymes by a thin polymeric layer (Figure 1: Structure). 
It has been proved that single enzyme nanocapsules, using 
organic/inorganic hybrid layer [10,12,13,14] organic acrylic 
copolymer [11,15], hyperhranched polymer layer [18] or super-
paramagnetic layer [19,20], can essentially stabilize enzymes. 
  
58(Sup), pp. 11-16, 2014
DOI:10.3311/PPch.7284
http://www.pp.bme.hu/ch/article/view/7284
Creative Commons Attribution b
research article
Imre Hegedüs 
Research Institute of Chemical and Process Engineering,
Univesity of Pannonia, Egyetem str. 10., H-8200 Veszprém, Hungary
e-mail: hegedus@mukki.richem.hu
Endre Nagy
Research Institute of Chemical and Process Engineering,
Univesity of Pannonia, Egyetem str. 10., H-8200 Veszprém, Hungary
Éva Kiss-Tóth Dojcsak, Adrienn Juhászné Szalai, Zita Lovrity,
János Emmer, Péter Koska, Bertalan Fodor
Department of Nanobiotechnology and Regenerative Medicine, 
University of Miskolc, Faculty of Health Care, Miskolc, Hungary
P Periodica Polytechnica
Chemical Engineering
12 Per. Pol. Chem. Eng. Imre Hegedüs / Éva Kiss-Tóth Dojcsak / Adrienn Juhászné Szalai et al.
The nano-capsule around the enzymes is multifunctional 
(Figure 1: Functions). Single protein nanocapsules have 
1) stabilization function a) mechanical stability, when under 
mechanical stress (circular stirring) the single enzyme nano-
capsules are more stable than natural enzymes (enzymes 
without nano-layer) [12,13,14]; b) heat stability: when at 
extremely high temperature (80°C) single enzyme nanocap-
sules have greater stability than natural enzymes [12,13,14]. 
c) pH-stability: at extremely acidic (pH = 1.5) or alkaline 
(pH = 12.0) pH-values the activity of single enzyme nanocap-
sules are not reduced essentially, while the natural enzymes 
almost loose their activities [12,14]. d) The polymer nano-
layer around the enzymes can retain the quaternary structure of 
enzymes e.g. β-xylosidase enzymes from Thermobifida fusca 
species (not published results). 2) Single protein nanocapsules 
increase the biological stability of enzymes against protease 
enzymes in the systemic circulation [21]. 3) Single protein 
nanocapsules have a drug carrier function a) they can carry 
the encapsulated proteins as drugs through the blood-brain 
barrier [15]; b) they also can deliver protein drugs at intra-
cellular level [21,22]. Polymers are usually used as protein 
drug carriers [23], but these micrometer-size carriers cannot 
stabilize proteins [24].
The immunogenity and nanotoxicity of SPNs has not been 
studied previously though it is essential for any biomedical 
applications. Haemoglobin molecules have enzyme-like func-
tion and its structural stability is essential for a good function. 
For this reason human haemoglobin molecules (HgB) were 
encapsulated and single haemoglobin nanocapsules (PAAHgB) 
were synthesized. Synthesis of artificial blood is one of the 
most invested research area worldwide. Encapsulation of hae-
moglobin is the most common technique used for artificial 
blood delivery [25]. Stability of PAAHgBs was investigated 
by the measurement of the size distribution and melting point 
analysis. Nano-sized therapeutics usually inducts an extremely 
complex immune response (complement activation, activation 
of granulocyte cells, vasoactive mediator actions, etc.) [26]. 
Basophilic granulocyte test measure the activation of allergic 
reaction by the samples. Investigation of biocompatibility of 




Chemicals: Acryloyl chloryde, (Sigma), disodium hydro-
genphosphate, potassium dihydrogenphosphate (Spektrum-3d, 
Fig. 1. Structure and functions of acrylamide-bisacrylamide nano-layer on single protein nanocapsules
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Scharlau), acrylamide, bisacrylamide (Sigma), tetramethyl 
ethylenediamin (Sigma), 3,5-dinitrosalicylic acid (Sigma), 
sodium metabisulphid (Spektrum-3D), phenol (Sigma), sodium 
peroxodisulphate (Sigma), N,N,N’,N’tetramethylethylenedia-
mine (TEMED, Sigma-Aldrich), BasoTest (Glycotope Biotech-
nology, Heidelberg, Germany), different types of liposomes 
(Seroscience Ltd), multiwall carbon nanotubes (MWCNT, 
University of Szeged). Instruments: Nanosizer ZS (Malvern), 
FACS Calibur (Becton Dickinson)
2.2 Methods
Preparation of single haemoglobin nanocapsules (PAAHgB): 
335 mg of human haemoglobin was solved in 25 ml of phos-
phate buffer (120 mM, pH = 7.15, with a three times ion 
exchanged water, specific conductivity: ρ = 8.15 μS). Modi-
fication of haemoglobin on the surface: the solution was 
cooled to 0°C and 112 μl acryloyl chloride was added and was 
stirred over a half an hour. 152 μl of acrylamide/bisacylamide 
(10: 1 molar ratio of acrylamide: bisacrylamide) and 2.53 mg 
ammoniumperoxodisulphate and 1.5 μl TEMED initiator was 
added into the solution under N2-atmosphere to initiate the 
polymerization reaction over 6 hours. For the separation of 
the reagents and byproducts dialysis was used (with a 12 mm 
diameter, 10 kDa cutoff dialysis tube, for 2 x 6 hours at 2°C 
with a 120 mM, pH = 7.15 phosphate buffer).
For direct basophil activation we studied the following 
nanomaterials: different kinds of functionalized multiwall car-
bon nanotubes (MWCNT: CNT-OH, CNT-COOH), nanofiber, 
micro- and nanosoot particles, polyacrylamide gel (PAA), 
polyacrylamide gel encapsulated haemoglobin (PAAHgB) and 
liposomes with various lipid composition. We determined the 
particle size, size distribution and zeta potential with Malvern 
NanoZS DLS instrument. The nanomaterials were incubated 
for 15 min with peripheral blood specimens and the degree of 
activated basophils (co-expression of IgE and CD63 markers 
on the cell surface) were examined by FACS analysis.
3 Results and discussion
3.1 Size distribution of single haemoglobin 
nanocapsules
The size distribution and melting point detection were meas-
ured by dynamic light scattering (DLS) method, Zetasizer 
Software Nano series, Zetasizer v6.20. The concentration of 
samples was 3.36 mg/ml. The melting point of natural HgB 
molecules (Figure 2A) and single haemoglobin nanocap-
sules was measured to analyse the stability of nanocapsules 
(Figure 2B). The melting point is the same in both cases and it 
means that the heat stability of single haemoglobin nanocap-
sules is not worse than the native haemoglobin molecules.
Size distribution was measured in the function of the concen-
tration of single haemoglobin nanocapsules (PAAHgB) and in 
the function of temperature (Figure 3). Polyacrylamidebisacry-
lamide gel (PAA) in a same molar ratio and weight was used as 
control material.
Results show that the size distribution of PAA is between 
100 nm and 1000 nm at 25°C (Figure 3). The mean size of 
PAAHgB sample is less than 10 nm at 25°C and 30°C. This size 
range is suitable for biomedical applications. Size distribution 
is homogeneous at these temperatures. The size distribution 
has two peaks at 45°C. One of these peaks falls in size range 
of less than 10 nm and the other one, in range of higher than 
1000 nm. At 48°C there is only one peak in the size distribu-
tion of PAAHgB and its mean value is larger than 1000 nm. 
These results show that the aggregation of PAAHgB is occur-
ring at about 40°C and the whole amount of PAAHgB is 
aggregated at 48°C.
3.2 Comparison of different nanomaterials 
containing haemoglobin molecules
3.2.1 Zeta potential
We compared the size and zeta potential of different types 
of native nanomaterials with single haemoglobin nanocapsules 
(Figure 4).
In a stock solution of the empty (PAA) and HgB loaded poly-
acrylamide gel particles (PAAHgB) (13.44 mg/ml HgB in both 
cases) had the highest size. The lower size was observed in the 
case of liposome samples. The distribution range was quite wide 
(except liposomes). The monodispersity of particles was the best 
also of these materials. The range of zeta potential was between 
-3.56 and -47.2.
Fig. 2. Melting point analysis A) natural haemoglobin as a control 
B) PAAHgB
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Zeta potential values larger than -35 mV yield better stabil-
ity of nanoparticle, while that generally results in short-term 
stability of the suspension in range between -10 mV and 
-30 mV. PAAHgB samples have low negative zeta potential and 
they aggregate in concentrated stock solution (13.44 mg/ml), but 
liposomes (LipA and LipB) have high zeta potential values.
3.3 Basophile activation test
The size, homogeneity and aggregation status are important 
physico-chemical parameters that determine the biological 
behaviour of nanomaterials, and ultimately toxicity. In addi-
tion, the chemical composition is also important. In our work 
we demonstrated that the nanomaterials play an important role 
in the activation process of basophils – as a part of allergic 
reactions. This effect depends on the above-mentioned param-
eters. According to our study the basophil activation capacity 
of PAAHgB nanoparticles is slightly elevated comparing to the 
background results, but it is significantly smaller than the posi-
tive control (fMLP) (Figure 5). The samples treated with wash 
solution instead of allergen were the negative control. The 
activation level of these samples gives the background activa-
tion of the system. In case of the same chemical composition 
(MWCNT) the different surface functionalization fundamen-
tally modifies the level of basophil activation. Strong basophil 
activation was found in the presence of CNT-OH. The lower 
rate of CD63 expression was measured in samples containing 
liposome particles (LipB, LipA, LipC) and nanofibers. Car-
boxyl functionalized CNT-COOH, PAA and PAAHgB induce 
also lower rate of CD63 marker.
Fig. 3. Size distribution of PAA and PAAHgB in different temperatures
Fig. 4. Comparison of the size and zeta potential of different nanomaterials
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4 Conclusions
Single haemoglobin nanocapsules were synthesized with 
acrylamide-bisacrylamide copolymer on the surface of the mol-
ecules (PAAHgB) and size, homogeneity, aggregation status, zeta 
potential and allergenic activity (Basophil activation test) was 
investigated. Natural HgB molecules and PAAHgB samples have 
the same melting point (38°C). The mean size of PAAHgB (the 
peak of the size distribution) is less, than 10 nm while the mean 
size of empty acrylamide-bisacrylamide copolymer particles 
(AA) higher than 100 nm. Under 40°C the PAAHgB aggregates 
and at 48°C the aggregation will be complete (the peak of its size 
distribution is higher than 1000 nm). The results show that the 
basophil activation values of PAAHgB nanoparticles in the case 
of basophil activation kit are in the normal area (0-20%), however 
they cause slight direct activation and degranulation on basophil 
cells when compared with negative control. PAAHgB should be 
enveloped into liposome in order to reduce its aggregation.
Fig. 5. Basophilic activation test values of different nanomaterials
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